Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of January 2019, specifically dated January 7, 2019. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate a press release (Exhibit 99.1) by reference into the company's Registration Statements on Forms F-3 and S-8.
Key Financial Metrics
The filing text does not provide specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing is a procedural submission to distribute a press release rather than a financial report.
Material Changes
The document does not contain comparative financial data or details on material changes versus prior periods. It solely references the issuance of a press release on January 7, 2019, the content of which is attached as an exhibit but not summarized in the body of this filing text.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the provided text. The filing notes that the press release (Exhibit 99.1) contains a quote from Dr. Piet Wigerinck, but the substance of this quote and the press release itself are not included in the input text.
Investor Verification Checklist
- Verify the actual content of the press release attached as Exhibit 99.1, as the filing text only references it.
- Confirm the specific announcement made by Galapagos NV on January 7, 2019, which is the primary purpose of this filing.
- Review the incorporated Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure and ongoing offerings.
- Note that the metadata company name "Lakefront Biotherapeutics NV" appears to be incorrect; the filing is for Galapagos NV.